3:54 PM
 | 
Jan 09, 2018
 |  BC Extra  |  Company News

Shire splits neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for its neurology franchise (see BioCentury Extra, Aug. 2, 2017).

CEO Flemming Ornskov announced the changes Monday at the J.P. Morgan Healthcare Conference in San Francisco, saying that establishing the two divisions would be the company's focus for 1H18. In August, Shire floated...

Read the full 370 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >